Andelyn Biosciences, a company that develops and manufactures cell and gene therapies, opened its new manufacturing headquarters, the Andelyn Corporate Center (ACC), in the Innovation District in Columbus, OH. The newly constructed state-of-the-art and regulatory-compliant facility complements Andelyn’s two existing facilities in Columbus.

With 180,000 square feet of office, laboratory, and manufacturing space, the ACC more than triples Andelyn’s footprint, ensuring the company will have the space and capabilities to meet the growing demand for its cell and gene therapy services.

Wade Macedone, CEO of Andelyn Biosciences, said, “The opening of the new Andelyn Corporate Center is a fitting tribute to our more than 20 years of leadership and innovation in the development and manufacture of viral vectors for gene therapy. The new facility includes 16 cGMP modular manufacturing suites with upstream, downstream, solution prep, and filling capabilities, along with quality control labs and warehouse and corporate headquarters space.

Macedone added, “This expansion significantly enhances the comprehensive Concept-to-Commercialization capabilities we provide to our biotechnology and pharmaceutical clients. We are proud of our record of success in this demanding field, with over 2,000 viral vector production runs and more than 450 cGMP batches delivered in support of more than 75 global gene therapy clinical trials.”